Loading MDGL detail
Loading ticker data...
Loading MDGL detail
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.
Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche.
Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Chart data unavailable
CONSHOHOCKEN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on April 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan.
Capricorn Fund Managers Ltd bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 6,600 shares of the biopharmaceutical company's stock, valued at approximately $3,843,000. Several other hedge funds also recently
Assenagon Asset Management S.A. purchased a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 5,390 shares of the biopharmaceutical company's stock, valued at approximately $3,139,000. Several other hedge funds and other
Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Summit Therapeutics shares could drop later this year if it doesn't earn approval for its leading candidate. Madrigal Pharmaceuticals and Axsome Therapeutics could move in the opposite direction.
Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) and SciSparc (NASDAQ: SPRC - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk. Earnings and Valuation This table compares Madrigal Pharmaceuticals and
CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 15, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Bamco Inc. NY bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 2,600 shares of the biopharmaceutical company's stock, valued at approximately $1,193,000. Other hedge funds also recently bought
ArrowMark Colorado Holdings LLC lowered its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 14.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 123,259 shares of the biopharmaceutical company's stock after selling 21,549 shares during the period. ArrowMark Colorado Holdings
Ally Bridge Group NY LLC bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 32,662 shares of the biopharmaceutical company's stock, valued at approximately $14,981,000. Madrigal Pharmaceuticals comprises about 9.1%
Alkeon Capital Management LLC bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 120,000 shares of the biopharmaceutical company's stock, valued at approximately $55,039,000. Alkeon Capital Management LLC owned
Barclays PLC lowered its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 20.4% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 49,912 shares of the biopharmaceutical company's stock after selling 12,762 shares during the quarter. Barclays PLC owned about 0.22% of Madrigal
Axsome Therapeutics has an exciting late-stage pipeline. Madrigal Pharmaceuticals is looking to dominate a large market with significant unmet needs.
CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation. Institutional and Insider Ownership 98.5% of Madrigal
